Review
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity

https://doi.org/10.1016/j.smim.2021.101533Get rights and content
Under a Creative Commons license
open access

Highlights

  • SARS-CoV-2 spike protein is showing genetic alterations.

  • SARS-CoV-2 variants are evading natural and vaccine induced immunity.

  • New SARS-CoV-2 variants are resisting antibody neutralization.

  • Most COVID-19 vaccines target spike-specific neutralizing antibodies.

  • Continuous updating of vaccines/antibodies is required.

Abstract

Responsible for more than 4.9 million deaths so far, COVID-19, caused by SARS-CoV-2, is instigating devastating effects on the global health care system whose impacts could be longer for the years to come. Acquiring a comprehensive knowledge of host-virus interaction is critical for designing effective vaccines and/or drugs. Understanding the evolution of the virus and the impact of genetic variability on host immune evasion and vaccine efficacy is helpful to design novel strategies to minimize the effects of the emerging variants of concern (VOC). Most vaccines under development and/or in current use target the spike protein owning to its unique function of host receptor binding, relatively conserved nature, potent immunogenicity in inducing neutralizing antibodies, and being a good target of T cell responses. However, emerging SARS-CoV-2 strains are exhibiting variability on the spike protein which could affect the efficacy of vaccines and antibody-based therapies in addition to enhancing viral immune evasion mechanisms. Currently, the degree to which mutations on the spike protein affect immunity and vaccination, and the ability of the current vaccines to confer protection against the emerging variants attracts much attention. This review discusses the implications of SARS-CoV-2 spike protein mutations on immune evasion and vaccine-induced immunity and forward directions which could contribute to future studies focusing on designing effective vaccines and/or immunotherapies to consider viral evolution. Combining vaccines derived from different regions of the spike protein that boost both the humoral and cellular wings of adaptive immunity could be the best options to cope with the emerging VOC.

Keywords

Spike protein
RBD
Mutation
Immunity
Vaccine
SARS-CoV-2

Cited by (0)

1

These authors contributed equally.